

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14875-0153US1</b>	Application No. <b>10/551,504</b>
	Applicant <b>Hiroyuki Tsunoda <i>et al.</i></b>		
	Filing Date <b>September 29, 2005</b>	Group Art Unit <b>1647</b>	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	11/910,117	08/2007	Igawa <i>et al.</i>			
	2	11/910,128	09/2007	Igawa <i>et al.</i>			
	3	11/916,979	08/2008	Igawa			
	4	12/304,514	12/2008	Yoshikubo <i>et al.</i>			
	5	5,837,242	11/1998	Holliger <i>et al.</i>			
	6	5,840,344	11/1998	Fukushima			
	7	5,885,574	03/1999	Elliott			
	8	6,126,980	10/2000	Smith <i>et al.</i>			
	9	6,132,992	10/2000	Ledbetter <i>et al.</i>			
	10	6,579,692	06/2003	Fukushima			
	11	6,719,972	04/2004	Gribben <i>et al.</i>			
	12	6,759,043	07/2004	Fukushima			
	13	2002/155537	10/2002	Carter <i>et al.</i>			
	14	2003/0147894	08/2003	Fukushima <i>et al.</i>			
	15	2003/0157100	08/2003	Fukushima <i>et al.</i>			
	16	2003/0157577	08/2003	Fukushima <i>et al.</i>			
	17	2003/0202975	10/2003	Tedder			
	18	2003/0211108	11/2003	Fukushima <i>et al.</i>			
	19	2004/0001828	1/1/2004	Tuscano <i>et al.</i>			
	20	2004/0073013	04/2004	Fukushima <i>et al.</i>			
	21	2004/0219643	11/2004	Winter <i>et al.</i>			
	22	2005/0214278	09/2005	Kakuta <i>et al.</i>			
	23	2005/0267222	12/2005	Iwata <i>et al.</i>			
	24	2006/0058511	03/2006	Tanikawa <i>et al.</i>			
	25	2006/0159673	07/2006	Kojima			
	26	2006/0269989	11/2006	Miyazaki <i>et al.</i>			
	27	2007/0087381	04/2007	Kojima			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	28	2009/0022687	01/2009	Matsumoto <i>et al.</i>			
	29	2009/0117097	05/2009	Igawa <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	30	CA 2272245	05/28/1998	Canada				
	31	CA 2 331 641	11/11/1999	Canada				
	32	EP 437 622	07/24/1991	Europe				
	33	EP 0 721 015	07/10/1996	Europe				
	34	EP 0 774 511	05/21/1997	Europe				
	35	EP 811 691	12/10/1997	Europe				
	36	EP 1 035 132	09/13/2000	Europe				
	37	EP 0 562 125	09/29/1993	Europe				
	38	EP 1 396 500	03/10/2004	Europe				
	39	EP 1 262 548	08/10/2008	Europe				
	40	DE 198 19 846	11/11/1999	Germany			Abstract only	
	41	JP 3-41033	02/21/1991	Japan			Abstract only	
	42	JP 7-503622	04/20/1995	Japan			Abstract only	
	43	JP 7236475	09/12/1995	Japan			Abstract only	
	44	JP 8-500979	02/06/1996	Japan			Abstract only	
	45	JP 10-505231	05/26/1998	Japan			Abstract only	
	46	JP 11-092500	04/06/1999	Japan			Abstract only	
	47	JP 2000-95800	04/04/2000	Japan			Abstract only	
	48	JP 2001/506135	05/15/2001	Japan			Abstract only	
	49	JP 2001-513999	09/11/2001	Japan			Abstract only	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	50	JP 2001-518930	10/16/2001	Japan			Abstract only	
	51	JP 2001-523971	11/27/2001	Japan			Abstract only	
	52	JP 2002-543822	12/24/2002	Japan			Abstract only	
	53	JP 2002-544173	12/24/2002	Japan			Abstract only	
	54	JP 2003-515323	05/07/2003	Japan			Abstract only	
	55	JP 2004-292455	10/21/2004	Japan			Abstract only	
	56	WO 91/16928	11/14/1991	WIPO				
	57	WO 92/19759	11/12/1992	WIPO			English abstract	
	58	WO 93/06862	04/15/1993	WIPO			English abstract	
	59	WO 94/05690	03/17/1994	WIPO				
	60	WO 94/13806	06/23/1994	WIPO				
	61	WO 96/27011	09/06/1996	WIPO				
	62	WO 96/34892	11/07/1996	WIPO				
	63	WO 96/36360	11/21/1996	WIPO				
	64	WO 97/01633	01/16/1997	WIPO				
	65	WO 97/10354	03/20/1997	WIPO			English abstract	
	66	WO 97/32601	09/12/1997	WIPO			English abstract	
	67	WO 98/22136	05/28/1998	WIPO			English abstract	
	68	WO 98/44001	08/10/1998	WIPO				
	69	WO 98/50431	11/12/1998	WIPO				
	70	WO 99/17364	04/08/1999	WIPO				
	71	WO 00/44788	08/03/2000	WIPO				
	72	WO 00/53634	09/14/2000	WIPO			English abstract	
	73	WO 00/069462	11/23/2000	WIPO				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 7-1-00	Application No. 51561
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda <i>et al.</i>	
		Filing Date September 29, 2005	Group Art Unit 1647

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	74	WO 00/75191	12/14/2000	WIPO				
	75	WO 01/036486	05/25/2001	WIPO				
	76	WO 01/44282	06/21/2001	WIPO				
	77	WO 01/70775	09/27/2001	WIPO				
	78	WO 01/77342	10/18/2001	WIPO				
	79	WO 01/87337	11/22/2001	WIPO				
	80	WO 02/094880	11/28/2002	WIPO			English abstract	
	81	WO 02/097033	12/05/2002	WIPO				
	82	WO 02/096457	12/05/2002	WIPO				
	83	WO 03/086324	10/23/2003	WIPO				
	84	WO 03/087163	10/23/2003	WIPO			English abstract	
	85	WO 2004/019966	03/11/2004	WIPO			English abstract	
	86	WO 04/037293	05/06/2004	WIPO			English abstract	
	87	WO 04/111233	12/23/2004	WIPO			English abstract	
	88	WO 05/056604	06/23/2005	WIPO			English abstract	
	89	WO 2005/107784	11/17/2005	WIPO			English abstract	

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	90	ANDRIS-WIDHOPF <i>et al.</i> , "Methods for the generation of chicken monoclonal antibody fragments by phage display," <i>Journal of Immunological Methods</i> , 242:159-181 (2000)
	91	ARNDT <i>et al.</i> , "Generation of a highly stable, internalizing anti-DC22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma," <i>Int. J. Cancer</i> , 107(5):822-829 (2003)
	92	AVENT <i>et al.</i> , "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," <i>Biochem. J.</i> , 251:499-505 (1988)
	93	BARTLEY <i>et al.</i> , "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> , 77:1117-1124 (1994)
	94	BAZIL <i>et al.</i> , "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," <i>Blood</i> , 86:502-511 (1995)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	95	BAZZONI <i>et al.</i> , "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(12):5376-5580 (1995)
	96	BERESFORD <i>et al.</i> , "Binding Characteristics and Tumor Targeting of a Covalently Linked Divalent CC49 Single-Chain Antibody," <i>Int. J. Cancer</i> , 81:911-917 (1999)
	97	BERGER <i>et al.</i> , "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)
	98	BODMER <i>et al.</i> , "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," <i>Nat. Cell Biol.</i> , 2:241-243 (2000)
	99	BROWN <i>et al.</i> , "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)
	100	BROWN <i>et al.</i> , "Integrin-associated protein (CD47) and its ligands," <i>Trends Cell Biology</i> , 11(3):130-135 (2001)
	101	BUCHSBAUM <i>et al.</i> , "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," <i>Clin. Cancer Res.</i> , 9:3731-3741 (2003)
	102	BURGESS <i>et al.</i> , "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>J. Cell Biol.</i> , 111:2129-2138 (1990)
	103	BURTHEM <i>et al.</i> , "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," <i>Blood</i> , 84(3):873-882 (1994)
	104	CALDAS <i>et al.</i> , "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Mol. Immunol.</i> , 39:941-952 (2003)
	105	CARON <i>et al.</i> , "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)
	106	CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: some practical advice," <i>Pharmaceutical Research</i> , 14(8):969-975 (1997)
	107	CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: theory and practice," <i>Pharma Biotechnol.</i> , 13:109-133 (2001)
	108	CARTER, "Bispecific human IgG by design," <i>J. Immunol. Methods</i> , 248:7-15 (2001)
	109	CEKAITE <i>et al.</i> , "Protein Arrays: A versatile toolbox for target identification and monitoring of patient immune responses," <i>Methods Mol. Biol.</i> , 360:335-348 (2007)
	110	CHIEN <i>et al.</i> , "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 86:5532-5536 (1989)
	111	CHIRGWIN <i>et al.</i> , "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> , 18(24):5294-5299 (1979)
	112	CHUNTHARAPAI <i>et al.</i> "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> , 166:4891-4898 (2001)
	113	CLACKSON <i>et al.</i> , "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Hiroyuki Tsunoda <i>et al.</i>	
		Filing Date September 29, 2005	Group Art Unit 1647
(37 CFR §1.98(b))			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	114	CLELAND <i>et al.</i> , "A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody," <i>Journal of Pharmaceutical Sciences</i> , 90(3):310-321 (2001)
	115	COCHLOVIUS <i>et al.</i> , "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," <i>Cancer Res.</i> , 60:4336-4341 (2000)
	116	COCHLOVIUS <i>et al.</i> , "Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells," <i>The Journal of Immunology</i> , 165:888-895 (2000)
	117	COOPER <i>et al.</i> , "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3978-3982 (1995)
	118	CREIGHTON, T., "Protein folding," <i>Biochem. J.</i> , 270(1):1-16 (1990)
	119	DANIEL <i>et al.</i> , "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," <i>Human Immunology</i> , 65(3):189-199 (2004)
	120	DE JONGE <i>et al.</i> , "Production and Characterization of Bispecific Single-Chain Antibody Fragments," <i>Mol. Immunol.</i> , 32:1405-1412 (1995)
	121	DE LEON <i>et al.</i> , "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," <i>BMC Cancer</i> , 9(48):1-9 (2009)
	122	DEGLI-ESPOSTI <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> , 186:1165-1170 (1997)
	123	DE SAUVAGE <i>et al.</i> , "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , 369:533-538 (1994)
	124	DESPLANCQ <i>et al.</i> , "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)
	125	DE ST. GROTH <i>et al.</i> , "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , 35:1-21 (1980)
	126	DILLMAN, "Monoclonal antibodies for treating cancer," <i>Ann. Int. Med.</i> , 11(7):592-603 (1989)
	127	DORAI <i>et al.</i> , "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)
	128	EIJSINK <i>et al.</i> , "Rational engineering of enzyme stability," <i>Journal of Biotechnology</i> , 113:105-120 (2004)
	129	EMERY <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> , 273:14363-14367 (1998)
	130	EWERT <i>et al.</i> , "Biophysical properties of human antibody variable domains," <i>J. Mol. Biol.</i> , 325:531-553 (2003)
	131	EWERT <i>et al.</i> , "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering," <i>Methods</i> , 34:184-199 (2004)
	132	EWERT <i>et al.</i> , "Structure-based improvement of the biophysical properties of immunoglobulin V <sub>H</sub> domains with a generalizable approach," <i>Biochemistry</i> , 42:1517-1528 (2003)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	133	FELGENHAUER <i>et al.</i> "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , 18(16):4927 (1990)
	134	FROKJAER <i>et al.</i> , "Protein drug stability: a formulation challenge," <i>Nature Rev Drug Discov.</i> 4:298-306 (2005)
	135	FUJIMOTO <i>et al.</i> , "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," <i>Blood</i> , 86(6):2174-2182 (1995)
	136	FUKUSHIMA <i>et al.</i> , "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," <i>Blood</i> , 80(8):1914-1922 (1992)
	137	FUKUSHIMA <i>et al.</i> , "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," <i>Blood</i> , 94(10):479A (1999)
	138	GALFRE <i>et al.</i> , "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)
	139	GALFRE <i>et al.</i> , "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , 277:131-133 (1979)
	140	GARCIA-GONZALEZ <i>et al.</i> , "Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation," <i>Journal of Immunological Methods</i> , 111:17-23 (1988)
	141	GIUSTI <i>et al.</i> , "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)
	142	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)
	143	GOLDSTEIN <i>et al.</i> , "Cytolytic and Cytostatic Properties of an Anti-Human FcγRI (CD64) × Epidermal Growth Factor Bispecific Fusion Protein," <i>J. Immunol.</i> , 158:872-879 (1997)
	144	GOMBOTZ <i>et al.</i> , "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)," <i>Pharmaceutical Research</i> , 11(5):624-632 (1994)
	145	GREENSPAN <i>et al.</i> , "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)
	146	GRELL <i>et al.</i> , "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytotoxicity," <i>Lymphokine and Cytokine Research</i> , 12(3):143-148 (1993)
	147	GRIFFITH <i>et al.</i> , "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> , 162:2597-2605 (1999)
	148	GRUBER <i>et al.</i> , "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in <i>Escherichia coli</i> ," <i>Journal of Immunology</i> , 152:5368-5374 (1994)
	149	GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)
	150	HOLLIGER <i>et al.</i> , "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)
	151	HOOGENBOOM <i>et al.</i> , "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Res.</i> , 19:4133-4137 (1991)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Hiroyuki Tsunoda <i>et al.</i>	
		Filing Date September 29, 2005	Group Art Unit 1647
(37 CFR §1.98(b))			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	152	HOPP <i>et al.</i> , "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)
	153	HORAN <i>et al.</i> , "Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)
	154	HOZUMI and TONEGAWA, "Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions," <i>Proc. Natl. Acad. Sci. USA</i> , 73(10):3628-3632 (1976)
	155	HUSTON <i>et al.</i> , "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883 (1988)
	156	ITOH <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991)
	157	JÄGER <i>et al.</i> , "Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen," <i>Journal of Molecular Biology</i> , 285:2005-2019 (1999)
	158	JIANG <i>et al.</i> , "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," <i>J. Biol. Chem.</i> , 280(6):4656-4662 (2005)
	159	JONES <i>et al.</i> , "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," <i>Biotechnology</i> , 9:88-89 (1991)
	160	KEARNEY, <i>et al.</i> , "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," <i>The Journal of Immunology</i> , 123(4):1548-1550 (1979)
	161	KEEN <i>et al.</i> , "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," <i>Cytotechnology</i> , 18(3):207-217 (Abstract) (1994)
	162	KIPRIYANOV and LITTLE, "Generation of Recombinant Antibodies," <i>Molecular Biotechnology</i> , 12:173-201 (1999) (from 148 family)
	163	KIPRIYANOV <i>et al.</i> , "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," <i>In. J. Cancer</i> , 77:763-772 (1998)
	164	KIPRIYANOV <i>et al.</i> , "Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics," <i>Journal of Molecular Biology</i> , 293:41-56 (1999)
	165	KOHLER, <i>et al.</i> , "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519 (1976)
	166	KONTERMANN, R., "Recombinant bispecific antibodies for cancer therapy," <i>Acta Pharmacol. Sin.</i> , 26(1):1-9 (2005)
	167	KORN <i>et al.</i> , "Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv," <i>The Journal of Gene Medicine</i> , 6:642-651 (2004)
	168	KORTT <i>et al.</i> , "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," <i>Eur. J. Biochem.</i> , 221:151-157 (1994)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	169	KORTT <i>et al.</i> , "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten- residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423-433 (1997)
	170	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)
	171	KREBBER <i>et al.</i> , "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)
	172	KUMAR <i>et al.</i> , "Molecular cloning and expression of the fabs of human autoantibodies in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 275(41):35129-35136 (2000)
	173	KURUCZ <i>et al.</i> , "Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria," <i>The Journal of Immunology</i> , 154:4576-4582 (1995)
	174	LARRICK, <i>et al.</i> , "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)
	175	LAW <i>et al.</i> , "Observations On The Effect Of A Folic-Acid Antagonist On Transplantable Lymphoid Leukemias In Mice," <i>Journal of the National Cancer Institute</i> , 10:179-193 (1949)
	176	LAZAR <i>et al.</i> , "Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Molecular and Cellular Biology</i> , 8:1247-1252 (1988)
	177	LE GALL <i>et al.</i> , "Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody," <i>Protein Engineering Design &amp; Selection</i> , 17(4):357-366 (2004)
	178	LEE <i>et al.</i> , "Reversible dimer formation and stability of the anti-tumour single chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FR-IR spectroscopy," <i>J. Mol. Biol.</i> , 320:107-127 (2002)
	179	LEI <i>et al.</i> , "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," <i>Journal of Bacteriology</i> , 169:4379-4383 (1987)
	180	LIN <i>et al.</i> , "Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon," <i>Biochemistry</i> , 14:1559-1563 (1975)
	181	LINDBERG <i>et al.</i> , "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_v\beta_3$ -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)
	182	LINDBERG <i>et al.</i> , "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," <i>J. Biol. Chem.</i> , 269:1567-1570 (1994)
	183	LITTLE <i>et al.</i> , "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000)
	184	LIU <i>et al.</i> , "Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association," <i>Biochem. J.</i> , 358:511-516 (2001)
	185	MAITY <i>et al.</i> , "Equilibrium unfolding of dimeric and engineered monomeric forms of Cro (F58W) repressor and the effect of added salts: evidence for the formation of folded monomer induced by sodium perchlorate," <i>Archives of Biochemistry and Biophysics</i> , 434:93-107 (2005)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	186	MARGULIES <i>et al.</i> , "Somatic Cell Hybridization of Mouse Myeloma Cells," <i>Cell</i> , 8:405-415 (1976)
	187	MARIUZZA <i>et al.</i> , "The structural basis of antigen-antibody recognition," <i>Annu. Rev. Biophys. Biophys. Chem.</i> , 16:139-159 (1987)
	188	MARSTERS <i>et al.</i> , "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," <i>Curr. Biol.</i> , 7:1003-1006 (1997)
	189	MARTSEV <i>et al.</i> , "Antiferritin single-chain antibody: a functional protein with incomplete folding?" <i>FEBS Letters</i> , 441:458-462 (1998)
	190	MATEO <i>et al.</i> , "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," <i>FASEB Journal</i> , 12(5):A1082 (1998)
	191	MAWBY <i>et al.</i> , "Isolation and characterization of CD47 glycoprotein: a multispreading membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," <i>Biochem. J.</i> , 304:525-530 (1994)
	192	MCGUINNESS <i>et al.</i> , "Phage diabody repertoires for selection of large number of bispecific antibody fragments," <i>Nature Biotechnology</i> , 14(9):1149-1154 (1996)
	193	MENG <i>et al.</i> , "The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies," <i>Clinical Cancer Research</i> , 10:1274-1281 (2004)
	194	METHIA <i>et al.</i> , "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> , 82(5):1395-1401 (1993)
	195	MERCHANT <i>et al.</i> , "An efficient route to human bispecific IgG," <i>Nature Biotechnology</i> , 16:677-681 (1996)
	196	MILILI <i>et al.</i> , "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," <i>Eur. J. Immunol.</i> , 26:63-69 (1996)
	197	MIZUSHIMA <i>et al.</i> , "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> , 18(17):5322 (1990)
	198	MOORE <i>et al.</i> , "Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor," <i>Biochemistry</i> , 38:13960-13967 (1999)
	199	MORI <i>et al.</i> , "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death and Differentiation</i> , 11:203-207 (2004)
	200	MULLIGAN <i>et al.</i> , "Synthesis of Rabbit $\beta$ -Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 $\beta$ -Globin Recombinant Genome," <i>Nature</i> , 277:108-114 (1979)
	201	NAKAYAMA <i>et al.</i> , "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)
	202	NIEBA <i>et al.</i> , "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved <i>in vivo</i> folding and physical characterization of an engineered scFv fragment," <i>Protein Engineering</i> , 10(4):435-444 (1997)
	203	NOHAILE <i>et al.</i> , "Altering dimerization specificity by changes in surface electrostatics," <i>PNAS</i> 98(6):3109-3114 (2001)
	204	O'BRIEN <i>et al.</i> , "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> , 14(6):1021-1023 (1986)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	205	OHTSUKA <i>et al.</i> , "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," <i>Oncogene</i> , 22:2034-2044 (2003)
	206	PAN <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818 (1997)
	207	PAN <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113 (1997)
	208	PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Chapter 8, p. 242 (1993)
	209	PEIPP <i>et al.</i> , "Bispecific antibodies targeting cancer cells," <i>Biochem. Soc. Trans.</i> , 30:507-511 (2002)
	210	PETTERSON <i>et al.</i> , "CD47 Signals T Cell Death," <i>J. Immunol.</i> , 7031-7040 (1999)
	211	PETTERSON, "CD47 and death signaling in the immune system," <i>Apoptosis</i> , 5:299-306 (2000)
	212	RAJAGOPAL <i>et al.</i> , "A form of anti-Tac (Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs," <i>Protein Engineering</i> , 10(12):1453-1459 (1997)
	213	REINHOLD <i>et al.</i> , "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," <i>J. Cell Science</i> , 108:3419-3425 (1995)
	214	RIDGWAY <i>et al.</i> , "'Knobs-into-holes' engineering of antibody C <sub>H</sub> 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996)
	215	RIECHMANN <i>et al.</i> , "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 332:323-327 (1988)
	216	REITER <i>et al.</i> , "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," <i>Protein Engineering</i> , 7(5):697-704 (1994)
	217	REITER <i>et al.</i> , "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," <i>Biochemistry</i> , 33:5451-5459 (1994)
	218	ROUE <i>et al.</i> "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," <i>Biochimie.</i> , 85:741-746 (2003)
	219	ROUSCH <i>et al.</i> , "Somatostatin displayed on filamentous phage as a receptor-specific agonist," <i>Br. J. Pharmacol.</i> , 125:5-16 (1998) (from 148 family)
	220	ROZSNYAY <i>et al.</i> , "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> , 37(2-3):197-205 (1993)
	221	SATO <i>et al.</i> , "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Research</i> , 53:851-856 (1993)
	222	SCHICKEL, <i>et al.</i> , "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," <i>Biochem. Cell. Biol.</i> , 80(2):169-176 (2002)
	223	SCHWARTZ <i>et al.</i> , "A superactive insulin: [B10-aspartic acid]insulin(human)," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:6408-6411 (1987)
	224	SCHWARTZ <i>et al.</i> , "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," <i>J. Biol. Chem.</i> , 268(27):19931-19934 (1993)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	225	SCHMIDT <i>et al.</i> , "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor," <i>Int. J. Cancer</i> , 65(4):538-546 (1996)
	226	SEGAL <i>et al.</i> , "Bispecific antibodies in cancer therapy," <i>Current Opinion in Immunology</i> , 11:558-582 (1999)
	227	SHALABY <i>et al.</i> , "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," <i>J. Exp. Med.</i> , 175:217-225 (1992)
	228	SHARMA <i>et al.</i> , "Study of IgM aggregation in serum of patients with macroglobulinemia," <i>Clin Chem Lab Med</i> , 38(8):759-764 (2000)
	229	SHERIDAN <i>et al.</i> , "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> , 277:818-821 (1997)
	230	SHIGETA <i>et al.</i> , "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," <i>Clin. Exp. Immunol.</i> , 42:458-462 (1980)
	231	SHIMBA <i>et al.</i> , "Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody," <i>FEBS Letters</i> , 360:247-250 (1995)
	232	SHIRE <i>et al.</i> , "Challenges in the development of high protein concentration formulations," <i>Journal of Pharmaceutical Sciences</i> , 93(6):1390-1402 (2004)
	233	SHULMAN <i>et al.</i> , "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-270 (1978)
	234	SKERRA, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ," <i>Gene</i> , 151:131-135 (1994)
	235	SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987)
	236	SONG <i>et al.</i> , "Light chain of natural antibody plays a dominant role in protein antigen binding," <i>Biochemical and Biophysical Research Communications</i> , 268:390-394, (2000)
	237	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)
	238	SPAARGAREN <i>et al.</i> , "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>The J. Biol. Chem.</i> , 266(3):1733-1739 (1981)
	239	STANCOVSKI <i>et al.</i> , "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695 (1991)
	240	TAN <i>et al.</i> , "Contributions of a highly conserved V <sub>H</sub> /V <sub>L</sub> hydrogen bonding interaction to scFv folding stability and refolding efficiency," <i>Biophysical Journal</i> , 75:1473-1482 (1998)
	241	TANG <i>et al.</i> , "Selection of linkers for a catalytic single-chain antibody using phage display technology," <i>The Journal of Biological Chemistry</i> , 271(26):15682-15686 (1996)
	242	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," <i>J. Exp. Med.</i> , 148:313-323 (1978)
	243	TURNER <i>et al.</i> , "Importance of the linker in expression of single-chain Fv antibody fragments: optimization of peptide sequence using phage display technology," <i>Journal of Immunological Methods</i> , 205:43-54 (1997)
	244	VAN DEN BURG <i>et al.</i> , "Selection of mutations for increased protein stability," <i>Curr. Opin. Biotechnol.</i> , 13(4):333-337 (2002)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Hiroyuki Tsunoda <i>et al.</i>	
(37 CFR §1.98(b))		Filing Date September 29, 2005	Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	245	VAN GEELLEN <i>et al.</i> , "Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines," <i>Br. J. Cancer</i> , 89(2):363-373 (2003)
	246	VERMA <i>et al.</i> , "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216:165-181 (1998)
	247	VIEILLE <i>et al.</i> , "Hyperthermophilic enzymes: sources, uses, and molecular mechanisms for thermostability," <i>Microbiology and Molecular Biology Reviews</i> , 65(1):1-43 (2001)
	248	VOLKEL <i>et al.</i> , "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Engineering</i> , 14(10):815-823 (2001)
	249	WALCZAK <i>et al.</i> , "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397 (1997)
	250	WANG <i>et al.</i> , "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 185:129-188 (1999)
	251	WANG <i>et al.</i> , "Lyophilization and development of solid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 203:1-60 (2000)
	252	WANG <i>et al.</i> , "Protein aggregation and its inhibition in biopharmaceutics," <i>International Journal of Pharmaceutics</i> , 289:1-30 (2005)
	253	WHITLOW <i>et al.</i> , "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability," <i>Protein Engineering</i> , 6(8):989-995 (1993)
	254	WILEY <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> , 3:673-682 (1995)
	255	WINKLER <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> , 265:4505-4514 (2000)
	256	WORN <i>et al.</i> , "Stability engineering of antibody single-chain Fv fragments," <i>J. Mol. Biol.</i> , 305:989-1010 (2001)
	257	XIE <i>et al.</i> , "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," <i>Nature Biotechnology</i> , 15(8):768-771 (1997)
	258	YANABU <i>et al.</i> , "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein lb monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)
	259	YARDEN <i>et al.</i> , "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> , 26(5):1434-1442 (1987)
	260	YELTON <i>et al.</i> , "Fusion of Mouse Myeloma and Spleen Cells," <i>Current Topics in Microbiology and Immunology</i> , 81:1-7 (1978)
	261	ZHU <i>et al.</i> , "Remodeling domain interfaces to enhance heterodimer formation," <i>Protein Science</i> , 6:781-788 (1997)
	262	ZHU <i>et al.</i> , "An efficient route to the production of an IgG-like bispecific antibody", <i>Protein Eng.</i> , 13:361-367 (2000)
	263	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages
	264	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page
	265	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	266	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages
	267	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages
	268	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages
	269	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated August 8, 2007 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages
	270	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 4 pages
	271	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages
	272	FISH & RICHARDSON, Amendment in Reply to Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages
	273	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages
	274	FISH & RICHARDSON, Amendment in Reply to Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages
	275	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/013063, mailed November 18, 2003, 2 pages
	276	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages
	277	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages
	278	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages
	279	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages
	280	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page
	281	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages
	282	FISH & RICHARDSON P.C., Reply to Office Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages
	283	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages
	284	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages
	285	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages
	286	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	287	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages
	288	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/550,934, mailed November 21, 2007, 7 pages
	289	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 21, 2007 in U.S. App. Ser. No. 10/550,934, filed April 16, 2008, 2 pages
	290	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed June 12, 2008, 27 pages
	291	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 12, 2008 in U.S. App. Ser. No. 10/550,934, filed December 12, 2008, 45 pages
	292	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/550,934, mailed March 16, 2009, 19 pages
	293	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696, mailed July 27, 2004, 5 pages
	294	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/004696, dated February 9, 2005, 10 pages
	295	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated March 31, 2006, 4 pages
	296	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/560,098, mailed July 13, 2007, 9 pages
	297	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 13, 2007 in U.S. App. Ser. No. 10/560,098 filed August 10, 2007, 6 pages
	298	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/560,098, mailed October 23, 2007, 17 pages
	299	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Final Office Action in U.S. App. Ser. No. 10/560,098, mailed September 11, 2008, 20 pages
	300	U.S. EXAMINER LYNN ANNE BRISTON, USPTO Interview Summary for App. Ser. No. 10/560,098, mailed June 5, 2009, 8 pages
	301	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated September 11, 2008 in U.S. App. Ser. No. 10/560,098, filed June 10, 2009, 12 pages
	302	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/560,098, mailed August 13, 2009, 21 pages
	303	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/008585, mailed September 7, 2004, 4 pages
	304	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/008585, 10 pages
	305	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages
	306	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages
	307	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed January 4, 2008, 8 pages

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14875-0153US1</b>	Application No. <b>10/551,504</b>
	Applicant <b>Hiroyuki Tsunoda <i>et al.</i></b>		
	Filing Date <b>September 29, 2005</b>		Group Art Unit <b>1647</b>

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	308	FISH & RICHARDSON P.C., Response to Restriction Requirement dated January 4, 2008 in U.S. App. Ser. No. 10/582,413, filed February 4, 2008, 2 pages
	309	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,413, mailed March 31, 2008, 17 pages
	310	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 31, 2008 in U.S. App. Ser. No. 10/582,413, filed June 30, 2008, 20 pages
	311	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed June 30, 2008, 2 pages
	312	U.S. EXAMINER BRADLEY DUFFY, USPTO Notice of Informal or Non-Responsive Amendment in U.S. App. Ser. No. 10/582,413, mailed October 20, 2008, 3 pages
	313	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 12, 2008, 4 pages
	314	FISH & RICHARDSON P.C., Amendment in Reply to Notice of Informal or Non-Responsive Amendment dated October 20, 2008 in U.S. App. Ser. No. 10/582,413, filed November 17, 2008, 10 pages
	315	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 25, 2008, 4 pages
	316	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 24, 2008, 4 pages
	317	U.S. EXAMINER BRADLEY DUFFY, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed March 11, 2009, 8 pages
	318	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 11, 2009 in U.S. App. Ser. No. 10/582,413, filed April 8, 2009, 8 pages
	319	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed June 25, 2009, 28 pages
	320	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages
	321	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages
	322	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser. No. EP 04 82 0305, dated October 6, 2008, 3 pages
	323	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,304, mailed November 20, 2008, 7 pages
	324	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 20, 2008 in U.S. App. Ser. No. 10/582,304, filed December 16, 2008, 3 pages
	325	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed April 1, 2009, 38 pages
	326	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated April 1, 2009 in U.S. App. Ser. No. 10/582,304, filed June 30, 2009, 15 pages
	327	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018501, mailed March 29, 2005, 2 pages
	328	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018501, dated November 4, 2005, 7 pages

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14875-0153US1</b>	Application No. <b>10/551,504</b>
	Applicant <b>Hiroyuki Tsunoda <i>et al.</i></b>		
	Filing Date <b>September 29, 2005</b>	Group Art Unit <b>1647</b>	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	329	EPO EXAMINER HELENA DOMINGUES, European Search Report for App. Ser. No. EP 04 82 0311, dated January 28, 2009, 4 pages
	330	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages
	331	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages
	332	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages
	333	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages
	334	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/306800, mailed May 16, 2006, 4 pages
	335	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/306800, dated October 3, 2007, 6 pages
	336	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/US2006/306803, mailed July 11, 2006, 4 pages
	337	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/US2006/306803, dated October 3, 2007, 6 pages
	338	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890, mailed July 18, 2006, 2 pages
	339	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/309890, dated November 19, 2007, 5 pages
	340	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/311575, mailed September 26, 2006, 3 pages
	341	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/311575, dated December 11, 2007, 5 pages
	342	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/311600, mailed August 29, 2006, 2 pages
	343	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/31160, dated December 11, 2007, 8 pages
	344	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/311625, mailed August 22, 2006, 2 pages
	345	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/311625, dated December 11, 2007, 4 pages
	346	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2007/061850, mailed August 7, 2007, 8 pages
	347	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/061850, dated December 16, 2008, 8 pages
	348	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,654, mailed May 26, 2009, 9 pages
	349	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser. No. 10/399,518, mailed November 25, 2005, 9 pages

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement                  by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	350	FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S. App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages
	351	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed March 27, 2006, 38 pages
	352	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed September 26, 2006, 26 pages
	353	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages
	354	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages
	355	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed December 28, 2006, 29 pages
	356	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App. Ser. No. 10/399,518, filed May 3, 2007, 22 pages
	357	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed June 7, 2007, 13 pages
	358	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages
	359	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed September 27, 2007, 5 pages
	360	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser. No. 10/399,518, mailed November 13, 2007, 3 pages
	361	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed January 31, 2008, 14 pages
	362	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App. Ser. No. 10/399,518, filed April 30, 2008, 7 pages
	363	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed August 4, 2008, 8 pages
	364	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed November 7, 2008, 4 pages
	365	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App. Ser. No. 10/399,518, filed October 23, 2008, 8 pages
	366	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed February 17, 2009, 12 pages
	367	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App. Ser. No. 10/399,518, filed May 18, 2009, 26 pages
	368	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages
	369	U.S. EXAMINER ELLY GERALD STOICA, USPTO Restriction Requirement in U.S. App. Ser. No. 11/913,229, mailed July 8, 2009, 6 pages
	370	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0153US1	Application No. 10/551,504
	Applicant Hiroyuki Tsunoda <i>et al.</i>		
	Filing Date September 29, 2005		Group Art Unit 1647

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	371	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506, mailed March 22, 2005, 3 pages
	372	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages
	373	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser. No. EP 04 82 0316, dated July 17, 2008, 3 pages
	374	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 06 73 0748, dated April 22, 2009, 7 pages
	375	EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages

Examiner Signature /Shulamith Shafer/	Date Considered 12/09/2009
--	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.